CLYM · Climb Bio, Inc.

The thesis

Climb Bio's first Phase 2 data for budoprutug in primary membranous nephropathy showed a real biological effect, and the shares fell after the report anyway. The next dated tests are the third-quarter results and the fourth-quarter 2026 updates in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Those updates decide whether the drug's activity extends beyond one kidney disease.

The company reported on 24 October 2026 at the American Society of Nephrology (ASN) Kidney Week that 13 patients in the 200 mg cohort had a mean 70% reduction in anti-PLA2R antibody at Week 12. Five of the 13 (38%) reached immunologic remission. The adjusted close was $10.12 on 28 October 2026, 43.3% below the $17.84 adjusted 52-week high and down 15.0% over three months. The 14-day Relative Strength Index (RSI, a 0–100 momentum gauge) was 44.8.

The narrative is maturing: the headline readout is out, analysts reiterated high targets between 26 October 2026 and 27 October 2026, and the next fresh information comes with the quarterly report and the ITP and SLE updates. The release reported no proteinuria results, which is the measure that matters most for patients with this disease.

Bullish and bearish views on Climb Bio, Inc.

The bull case on Climb Bio, Inc. (CLYM), in brief: Antibody reduction matches the earlier trial. The bear case: The remission rate is modest and open-label.

Bull case

• Antibody reduction matches the earlier trial. The 24 October 2026 release reports a 70% mean anti-PLA2R reduction at Week 12 in the 200 mg cohort, and 80% in patients with baseline levels below 175 RU/mL. The company says this is consistent with its Phase 1b data.
• A higher dose is already showing deeper depletion. In the 600 mg cohort, mean peripheral CD20-positive B-cell suppression at Week 4 was 98%, against 74% at 200 mg (company release, 24 October 2026). Guggenheim wrote on 26 October 2026 that the Phase 3 dose will likely exceed 200 mg.
• Safety looks clean so far. The company reported no treatment-related serious adverse events, discontinuations or deaths at 200 mg and 600 mg. This is cleaner than the neutropenia case in the ASN abstract that Raymond James described on 5 October 2026.
• Analysts stay far above the price. Piper Sandler reiterated Overweight with a $40 target (Investing.com, 27 October 2026). Guggenheim holds $35 with a Buy rating, Raymond James $34, and BTIG $32 (27 October 2026). Deutsche Bank initiated coverage on 20 October 2026 with a Buy rating and a $28 target.
• The second drug supports a Phase 3 plan. Climb and Mabworks reported on 23 October 2026 that Phase 1 data support quarterly CLYM116/MIL116 dosing in IgA nephropathy, with a Phase 3 trial expected in 2027. Guggenheim cites a half-life of about 33 days and free-APRIL suppression above 90% through Week 12.
• Cash covers the plan. Climb reported $239.2 million in cash, equivalents and marketable securities at 30 June 2026 and guided funding into the second half of 2028 (second-quarter release, 6 August 2026).

Bear case

• The remission rate is modest and open-label. Five of 13 patients reached immunologic remission at Week 12 with no control arm (company release, 24 October 2026). Most of the cohort did not reach remission at this dose.
• No proteinuria data yet. The release contained no proteinuria response for the trial cohorts. The company instead cited a population analysis of about 120 patients showing that high-proteinuria patients clear budoprutug at least twice as fast, which it uses to support higher doses.
• The 600 mg result is a biomarker only. The 600 mg cohort has follow-up through Week 6, with no patient count, antibody or remission figures (company release, 24 October 2026). The 1000 mg cohort is still enrolling, and the next PrisMN data are guided for 2027.
• The shares fell after the data. Investing.com quoted $10.19 on 26 October 2026 and $9.21 on 27 October 2026, and reported an 18% decline over the prior week. Piper Sandler said investors were not recognising the strength of the data. The adjusted close was $10.12 on 28 October 2026.
• Insider and placement supply remain. Director Stephen Thomas sold 100,000 shares at $13.67 on 15 September 2026 (SEC Form 4, reported by MarketBeat on 23 September 2026). A resale registration filed 29 May 2026 covers up to 11.59M shares issued at $9.50 in the 28 April 2026 private placement.

Price setup

The adjusted close was $10.12 on 28 October 2026, against $10.91 on 15 October 2026 and a 52-week high of $17.84 (split/dividend-adjusted daily closes). The shares sit 43.3% below that high and 6.5% above the $9.50 private placement price. Investing.com's quote of $9.21 on 27 October 2026 means the shares traded below the placement price within the past two sessions.

The RSI was 44.8 on 28 October 2026, up from 16.0 in early October, so selling momentum has eased. The consensus target was $26.92 with a range of $20 to $32 (MarketBeat, 23 September 2026). Since then Piper Sandler has set $40 and Deutsche Bank $28.

Crowding evidence is mixed. RA Capital-affiliated entities are a reported 10% owner in Form 4 filings, and the placement shares are registered for resale. Investing.com put the one-year gain at 319% on 27 October 2026, so the shares carry high expectations despite the pullback. The third-quarter report is the next scheduled event.

Catalysts, next 30 days

• Q4 2026 (company-guided): Budoprutug ITP and SLE updates. Piper Sandler lists additional Phase 1b/2a ITP data and initial Phase 1b global SLE data in the fourth quarter. A slip past 31 December 2026 would break the guided timetable.
• 2027: Further PrisMN data and CLYM116 Phase 2 IgA nephropathy data (company-guided, first half of 2027). Later than 30 days, but the 600 mg and 1000 mg cohorts decide the Phase 3 dose.

Elapsed catalysts

• ~5 November 2026 (est.): Third-quarter 2026 results and 10-Q. Shows research spending against the $9.7 million second-quarter level and whether the runway into the second half of 2028 holds. (passed 1d ago)

What would change the view

The case breaks if the next data show budoprutug's effect is confined to antibody markers, with no proteinuria improvement when it is reported. It also breaks if the ITP or SLE updates slip past 31 December 2026 or show no response. A new serious adverse event at 600 mg or 1000 mg would damage the clean safety record to date. A third-quarter report showing research spending well above the second-quarter level, or a shorter funding runway, would weaken the financing argument.

On price, a daily close below $9.00 would put the shares under the $9.21 level Investing.com quoted on 27 October 2026 and under the $9.50 placement price. That would show the post-data selling had continued.

What it trades with

Clinical-stage biotech shares of this size tend to move with small-cap biotech sentiment and financing conditions. No current theme carries this name, so its price rests on its own trial results. CLYM116 trades against other anti-APRIL programs in IgA nephropathy, and the partner Beijing Mabworks Biotech runs the China studies, so those timelines depend on a third party.